[go: up one dir, main page]

BR9909266A - Formulações efervescentes - Google Patents

Formulações efervescentes

Info

Publication number
BR9909266A
BR9909266A BR9909266-2A BR9909266A BR9909266A BR 9909266 A BR9909266 A BR 9909266A BR 9909266 A BR9909266 A BR 9909266A BR 9909266 A BR9909266 A BR 9909266A
Authority
BR
Brazil
Prior art keywords
alkali
effervescent
sensitive active
formulations
effervescent formulations
Prior art date
Application number
BR9909266-2A
Other languages
English (en)
Inventor
Wolfram Tritthart
Maria Andre Maildorf Piskernig
Gottfried Koelbl
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of BR9909266A publication Critical patent/BR9909266A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçõES EFERVESCENTES"<D>. A invenção refere-se a formas de preparação rapidamente decomponíveis para substâncias ativas sensíveis a álcali, particularmente selegilina para emprego oral na forma de formulações efervescentes que contêm uma substância ativa sensível a álcali e uma base efervescente consistindo em um ou mais carbonatos alcalino-terrosos, um ácido orgânico comestível e/ou um sal alcalino do ácido cítrico, e opcionalmente coadjuvantes farmaceuticamente empregáveis.
BR9909266-2A 1998-03-31 1999-03-20 Formulações efervescentes BR9909266A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814257A DE19814257A1 (de) 1998-03-31 1998-03-31 Brauseformulierungen
PCT/DE1999/000798 WO1999049842A1 (de) 1998-03-31 1999-03-20 Brauseformulierungen

Publications (1)

Publication Number Publication Date
BR9909266A true BR9909266A (pt) 2000-11-21

Family

ID=7863015

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909266-2A BR9909266A (pt) 1998-03-31 1999-03-20 Formulações efervescentes

Country Status (28)

Country Link
US (1) US6242002B1 (pt)
EP (1) EP1067905B1 (pt)
JP (1) JP4469494B2 (pt)
KR (1) KR100607395B1 (pt)
CN (1) CN1138529C (pt)
AR (1) AR018829A1 (pt)
AT (1) ATE224703T1 (pt)
AU (1) AU753194B2 (pt)
BG (1) BG65043B1 (pt)
BR (1) BR9909266A (pt)
CA (1) CA2326502C (pt)
CZ (1) CZ300705B6 (pt)
DE (2) DE19814257A1 (pt)
DK (1) DK1067905T3 (pt)
ES (1) ES2183555T3 (pt)
HU (1) HU229793B1 (pt)
IL (1) IL138605A (pt)
NO (1) NO329143B1 (pt)
NZ (1) NZ506989A (pt)
PL (1) PL192049B1 (pt)
PT (1) PT1067905E (pt)
RU (1) RU2221554C2 (pt)
SK (1) SK284477B6 (pt)
TR (1) TR200002812T2 (pt)
TW (1) TW580398B (pt)
UA (1) UA66847C2 (pt)
WO (1) WO1999049842A1 (pt)
ZA (1) ZA200005133B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
AU2004242477B2 (en) * 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
AU2007203233B2 (en) * 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
BR0109544A (pt) * 2000-03-28 2003-06-10 Biochemie Gmbh Partìculas granuladas com sabor ocultado
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040175456A1 (en) * 2003-03-06 2004-09-09 Lauren Keilbach Tablets for feeding fish and methods of making tablets for feeding fish
US20040191298A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
ATE500821T1 (de) * 2003-12-31 2011-03-15 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US20050142197A1 (en) 2003-12-31 2005-06-30 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US7033511B2 (en) 2004-01-20 2006-04-25 A-Dec, Inc. Sustained water treatment in dental equipment
JP2008500288A (ja) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー 経口治療用化合物の供給系
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US9757455B2 (en) * 2005-11-28 2017-09-12 Johnson & Johnson Consumer Inc. Oral therapeutic compound delivery system
EP2361081B1 (en) * 2008-10-14 2016-06-29 McNeil AB Multi portion intra-oral dosage form and use thereof
KR101233352B1 (ko) * 2009-04-22 2013-02-25 (주)비씨월드제약 유전자 재조합 과립구-대식세포 집락 촉진인자를 함유하는 정제
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CA2863613C (en) 2012-02-01 2020-10-27 Intercontinental Great Brands Llc Low calorie drink tablet
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN109303334B (zh) * 2018-10-17 2021-04-13 汤臣倍健股份有限公司 一种口腔微泡腾片及其制备方法
ES2945809T3 (es) * 2019-10-02 2023-07-07 Intas Pharmaceuticals Ltd Composiciones farmacéuticas sólidas efervescentes prácticamente sin sodio
CN115551982A (zh) * 2020-05-28 2022-12-30 联合利华知识产权控股有限公司 片剂
CA3181912A1 (en) 2020-06-08 2021-12-16 Anthony Richard Gerardi Effervescent oral composition comprising an active ingredient

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
DE3440288C2 (de) * 1984-11-05 1987-03-12 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung
US4687662A (en) * 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
HU209605B (en) 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
CA2112663C (en) * 1991-07-01 2002-04-23 Thomas Gergely Effervescent systems using reaction doping agents
ES2074769T3 (es) 1991-07-01 1995-09-16 Gergely Gerhard Procedimiento para la elaboracion de un preparado farmaceutico con, al menos, dos principios activos diferentes y uso de un preparado de este tipo.
EP0593807A1 (en) 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH &amp; Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
DE69334237D1 (de) * 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycinrezeptorantagonisten und ihre verwendung
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
FR2698788B1 (fr) * 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
AU6764794A (en) * 1993-01-27 1994-08-29 Affymax Technologies N.V. Compositions and methods for transdermal drug delivery
US5287394A (en) 1993-03-22 1994-02-15 Advanced Micro Devices, Inc. Fast counter with uniform delay structures
SE9301112D0 (sv) 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
ATE140621T1 (de) * 1993-04-15 1996-08-15 Gergely Gerhard Brausesystem mit einem alkali- und/oder metallempfindlichen, pharmazeutischen wirkstoff, und verfahren zur herstellung
EP0813865B1 (de) 1993-04-20 2001-09-19 Hexal Ag Wirkstoffpflaster
US5503844A (en) 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
ES2126147T3 (es) 1993-09-09 1999-03-16 Gerhard Gergely Granulado efervescente y procedimiento para su preparacion.
EP0728036B1 (de) 1993-11-12 1998-01-14 Gerhard Gergely Verfahren zum herstellen von granulat
RU2043099C1 (ru) * 1994-01-31 1995-09-10 Анатолий Евгеньевич Добротворский Фармацевтическая композиция в форме шипучих таблеток и способ ее получения
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
US5603955A (en) 1994-07-18 1997-02-18 University Of Cincinnati Enhanced loading of solutes into polymer gels
HU223475B1 (hu) 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
DE29500718U1 (de) * 1995-01-18 1995-04-06 Rau, Reinhard, 37242 Bad Sooden-Allendorf Element einer Zeltplane zum Aufbau von kohten- und jurtenähnlichen Zeltaufbauten
WO1997017067A1 (en) 1995-11-06 1997-05-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline

Also Published As

Publication number Publication date
NO20004721D0 (no) 2000-09-21
DK1067905T3 (da) 2003-02-03
JP2002509872A (ja) 2002-04-02
HU229793B1 (en) 2014-07-28
ZA200005133B (en) 2001-02-28
ES2183555T3 (es) 2003-03-16
PT1067905E (pt) 2003-02-28
CA2326502C (en) 2008-08-05
PL192049B1 (pl) 2006-08-31
TW580398B (en) 2004-03-21
CN1138529C (zh) 2004-02-18
PL343260A1 (en) 2001-07-30
CZ300705B6 (cs) 2009-07-22
AU753194B2 (en) 2002-10-10
RU2221554C2 (ru) 2004-01-20
DE19814257A1 (de) 1999-10-07
BG65043B1 (bg) 2007-01-31
EP1067905B1 (de) 2002-09-25
AR018829A1 (es) 2001-12-12
CZ20003482A3 (en) 2001-05-16
KR20010042317A (ko) 2001-05-25
IL138605A0 (en) 2001-10-31
DE59902843D1 (de) 2002-10-31
HUP0101427A2 (hu) 2001-08-28
ATE224703T1 (de) 2002-10-15
IL138605A (en) 2005-11-20
NO20004721L (no) 2000-09-21
TR200002812T2 (tr) 2001-01-22
NO329143B1 (no) 2010-08-30
HK1036010A1 (en) 2001-12-21
WO1999049842A1 (de) 1999-10-07
HUP0101427A3 (en) 2001-12-28
CA2326502A1 (en) 1999-10-07
KR100607395B1 (ko) 2006-08-02
JP4469494B2 (ja) 2010-05-26
SK284477B6 (sk) 2005-04-01
BG104841A (en) 2001-07-31
SK14322000A3 (sk) 2001-07-10
UA66847C2 (uk) 2004-06-15
US6242002B1 (en) 2001-06-05
NZ506989A (en) 2002-09-27
CN1295463A (zh) 2001-05-16
AU4029499A (en) 1999-10-18
EP1067905A1 (de) 2001-01-17

Similar Documents

Publication Publication Date Title
BR9909266A (pt) Formulações efervescentes
ES2152966T3 (es) Formas de dosificado farmaceuticas de desleido rapido y procedimiento para su preparacion.
DE69942921D1 (de) Osmotische Dosierungsform mit verlängerter Wirkstoffabgabe
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
AR018828A1 (es) Formulaciones efervescentes solidas de rapida desintegracion para administracion oral.
ATE253896T1 (de) Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
CO4600739A1 (es) Formulaciones liquidas orales a base de alendronato
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
SI1526839T1 (sl) Oralne farmacevtske oblike tekočih zdravil z izboljšano biološko uporabnostjo
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
DE69532415D1 (de) Schmelzextrudierte oral verabreichbare opioidformulierungen
DE69233130D1 (de) Kaubare zusammensetzung zur arzneimittelfreisetzung
EP0960621A3 (en) Pharmaceutical formulations comprising sildenafil
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
ATE529097T1 (de) Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff
ES2195638T3 (es) Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida.
AR036937A1 (es) Tableta masticable que contiene lisina
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
ATE318575T1 (de) Orale zubereitung chlorhexidin und maltitol oder erythritol oder deren mischung enthaltend
AR087240A2 (es) Composiciones farmaceuticas que tienen epinastina y pseudoefedrina
AR020205A1 (es) Formulacion efervescente esterilizante.
DE60006000D1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung

Legal Events

Date Code Title Description
TC Change of name
PC Transfer

Owner name: ASTA MEDICA HEALTH PRODUCTS GMBH & CO. KG (DE)

TC Change of name
B25G Requested change of headquarter approved

Owner name: VIATRIS GMBH AND CO. KG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050037237/RJ DE 17/05/2005.

B25D Requested change of name of applicant approved

Owner name: MEDA PHARMA GMBH AND CO. KG (DE)

Free format text: ALTERADO DE: VIATRIS GMBH AND CO. KG

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.